Malignancy Risk Index 4 (RMI 4) is better than RMI 3 as a predictor Advanced Epithelial Ovarian Carcinoma was used for NACT

Authors

  • Putu Arik Herliawati STIKES Advaita Medika Tabanan
  • Dhian Eka Putri Harnandari Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Brawijaya
  • Rezha Alivia Hildayanti Department of Midwifery, STIKES Kendedes Malang
  • Arghya Wicaksana Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Brawijaya
  • Pande Putu Firsta Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Brawijaya

DOI:

https://doi.org/10.31004/jn.v7i1.13495

Abstract

Of the 4 cancers in women, ovarian carcinoma is the first cause of death. The low survival rate in patients with advanced stages requires early detection to improve treatment outcomes. The methods currently used to determine whether a patient can be given neoadjuvant chemotherapy are ascites cytology and laparoscopy.This study aims To compare RMI 4 and RMI 3 as a non-invasive method in determining preoperative NACT administration. The method used is RMI 3 and RMI 4 diagnostic scoring where this method can be used as a predictor of advanced epithelial ovarian carcinoma in the interest of NACT. An analytical observational study with a retrospective cross sectional type study with samples of all patients suffering from ovarian cancer for the past 5 years, from January 2016 to January 2020 who had been diagnosed at the Gynecology Polyclinic RSUD dr. Saiful Anwar. The number of initial samples of this study was 253 women, but after being included in the inclusion criteria, there were 106 samples. After staging by an authorized clinician, there were 48 patients with early stage and 58 patients with advanced stage. Between the results of the RMI score and the histopathological results on the ROC curve, it was found that the accuracy value of RMI 3 is 84.9% and the accuracy value of RMI 4 is 86.8%. It can be concluded that RMI 4 is better than RMI 3 as a predictor of advanced ovarian carcinoma to determining preoperative NACT administration.

Downloads

Published

2023-04-15

How to Cite

Herliawati, P. A. ., Harnandari, D. E. P. ., Hildayanti, R. A. ., Wicaksana, A. ., & Firsta, P. P. . (2023). Malignancy Risk Index 4 (RMI 4) is better than RMI 3 as a predictor Advanced Epithelial Ovarian Carcinoma was used for NACT. Jurnal Ners, 7(1), 536–542. https://doi.org/10.31004/jn.v7i1.13495

Issue

Vol. 7 No. 1 (2023): APRIL 2023

Section

Articles

License

Copyright (c) 2023 Jurnal Ners

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike 4.0 International License that allows others to share the work with an acknowledgement of the works authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journals published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).